About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Kevin Riley, Production Coordinator
Statement of Purpose
Guidelines for Authors
Topics include Medicare Part D, informatics, and the paper edition of P&T.
Jacob Hutti, PharmD; Joseph A. Catapano, MD, FACC, MMM; and Teri Luebbering, RPh, CGP, FASCP
Health Care and Law
Dr. Field presents the case for and against the FDA’s proposed new limits for pharmaceutical manufacturers in marketing and promoting off-label uses of drugs.
Robert I. Field, JD, MPH, PhD
Presentations cover comparisons of daptomycin (Cubicin for Injection) and vancomycin (Vancocin) for skin infections and recombinant human thrombin versus bovine-derived thrombin for controlling hemostasis during surgery.
Topics include desvenlafaxine (Pristiq) for major depressive disorder in adults; rilonacept (Arcalyst) in treating inflammatory syndromes; and levocetirizine (Xyzal Oral Solution) for symptoms associated with allergic rhinitis and hives.
Marvin M. Goldenberg, PhD, RPh, MS
Continuing Education Credit
The authors discuss current and investigational therapies for this debilitating illness, the adverse events associated with its treatment, and some protocols for preventing stroke and infection.
Uche Anadu Ndefo, PharmD, BCPS; Angie Eaton Maxwell, PharmD; Huong Nguyen, PharmD Candidate; and Tochukwu L. Chiobi, PharmD
David Nash, MD, MBA, reviews Slaves to Medicine, a controversial book by Dr. George Beauchamp that addresses the runaway economy in health care today.
David Nash, MD, MBA
Matthew Grissinger, RPh, FASCP, offers tips for preventing confusion of morphine with hydromorphone, both potent narcotics.
Matthew Grissinger, RPh, FASCP
Stephen Barlas explores the increase in deaths from prescription drugs, especially from narcotic overdoses, as in the recent case of actor Heath Ledger.
From Arcalyst to Zotarolimus, P&T presents the latest information on FDA approvals, new indications, recalls, and industry updates.
The authors review the selegiline transdermal system (Emsam) for major depressive disorder.
Lois Jessen, MS, PharmD, Lawrence J. Kovalick, PharmD, and Albert J. Azzaro, PhD